| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -7,151,469 |
| Depreciation and amortization | 323,653 |
| Stock-based compensation | 278,547 |
| Non-cash lease expense | 294,026 |
| Warrant inducement expense | 0 |
| Prepaid expenses and other current assets | -151,550 |
| Accounts payable and other current liabilities | -383,384 |
| Due to related parties | -511,315 |
| Net cash used in operating activities | -6,998,392 |
| Purchases of property and equipment | 3,704 |
| Cash used in investing activities | -3,704 |
| Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units | 10,915 |
| Gross proceeds from the issuance of common stock and pre-funded warrants | 6,901,465 |
| Payments for offering costs related to equity issuance | 1,087,854 |
| Proceeds from exercise of warrants standard terms | 0 |
| Proceeds from exercise of warrants induced terms | 848,537 |
| Commission paid related to warrant inducement | 0 |
| Legal fees paid related to warrant inducement | 0 |
| Payments for deferred offering costs related to future equity issuance | 129,329 |
| Net cash provided by financing activities | 6,521,904 |
| Effect of exchange rate on changes on cash | 6,504 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -473,688 |
| Cash and cash equivalents restricted cash at beginning of year | 5,599,074 |
| Cash and restricted cash | 5,125,386 |
AETHLON MEDICAL INC (AEMD)
AETHLON MEDICAL INC (AEMD)